Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study
18d ago1 min readNews
From the article
DurHope phase 2 study: 30 HCC patients with Vp3/4 PVTT received durvalumab + HAIC-FOLFOX. Primary endpoint: 1-yr OS rate. Could this new approach improve outcomes? Discuss! PMID:42151180, Nat Commun 2026, @NatureComms #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Continue reading on doi.orgYou might also wanna read
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
clinicaltrials.gov·8d ago
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·1d ago
First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
clinicaltrials.gov·8d ago
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
clinicaltrials.gov·7d ago
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
clinicaltrials.gov·2d ago
A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors
clinicaltrials.gov·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.